Showing results (1531-1540 of 3,637) with videos related to

Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|November 3, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysisYouwen Zhu, Kun Liu, Min Wang, et al.
Breast (Edinburgh, Scotland)|November 3, 2022
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapyJae Ho Jeong, Sung-Bae Kim
Breast (Edinburgh, Scotland)|November 6, 2022
Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancerEoin P Kerin, Matthew G Davey, Ray P McLaughlin, et al.
Breast (Edinburgh, Scotland)|November 4, 2022
Acinic cell carcinoma of the breast: A comprehensive reviewAzra Ajkunic, Faruk Skenderi, Nada Shaker, et al.
Breast (Edinburgh, Scotland)|September 16, 2022
Prognosis stratification and postoperative radiation therapy utilization in adenoid cystic carcinoma of the breastDi Zhang, Lixi Li, Fei Ma
Breast (Edinburgh, Scotland)|November 5, 2022
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancerElie Rassy, Layal Rached, Barbara Pistilli
Breast (Edinburgh, Scotland)|October 4, 2022
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancerAmit Bahl, William Wilson, Jessica Ball, et al.
Breast (Edinburgh, Scotland)|February 17, 2022
On top of that all, now Covid-19, too. A scoping review of specificities and correlates of fear of cancer recurrence in breast cancer patients during COVID-19Éva Kállay, Flavia Medrea, Csaba László Dégi
Breast (Edinburgh, Scotland)|April 14, 2019
Patient-reported health problems and healthcare use after treatment for early-stage breast cancerK M de Ligt, M Heins, J Verloop, et al.
Breast (Edinburgh, Scotland)|May 18, 2019
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicityEdy Ippolito, Carlo Greco, Sonia Silipigni, et al.
Pageof 364